Cerus Corp
Veridion Score
Composite trend over time
Why is CERS moving today?
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CERS.
CERS insider activity
Cerus Corp
No multi-insider buying cluster in the last 90 days
Net selling: -$2.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | 2026-06-09 | BJERKHOLT ERIC | Insider | sell | $2.60 | 20,454 | 261,679 | $53K | SEC Form 4 |
| 2026-06-02 | 2026-05-29 | Jayaraman Vivek K | Insider | sell | $3.00 | 16,667 | 1,656,707 | $50K | SEC Form 4 |
| 2026-05-05 | 2026-05-01 | Jayaraman Vivek K | Insider | sell | $3.00 | 16,667 | 1,673,374 | $50K | SEC Form 4 |
| 2026-03-16 | 2026-03-12 | Jayaraman Vivek K | Insider | sell | $1.66 | 165,200 | 1,747,674 | $274K | SEC Form 4 |
| 2026-03-16 | 2026-03-12 | Green Kevin Dennis | Insider | sell | $1.66 | 127,544 | 1,040,551 | $211K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 15 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCERS contract awards, year to date.
Public federal awards linked to this ticker.
CERS lobbying filings, year to date.
Registered lobbying filings matched to Cerus Corp.